182 related articles for article (PubMed ID: 31954171)
21. Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma.
Gahrton G
Lancet Haematol; 2017 Jun; 4(6):e250-e251. PubMed ID: 28522109
[No Abstract] [Full Text] [Related]
22. Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.
Doudican NA; Wen SY; Mazumder A; Orlow SJ
Oncol Rep; 2012 Nov; 28(5):1851-8. PubMed ID: 22922937
[TBL] [Abstract][Full Text] [Related]
23. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
24. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
[TBL] [Abstract][Full Text] [Related]
25. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
[TBL] [Abstract][Full Text] [Related]
27. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
28. Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells.
Zhao Y; Zhang E; Lv N; Ma L; Yao S; Yan M; Zi F; Deng G; Liu X; He J; Wu W; Cai Z; Yu R
Cell Physiol Biochem; 2018; 48(2):785-800. PubMed ID: 30032136
[TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
30. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
Nieto Y; Popat U; Anderlini P; Valdez B; Andersson B; Liu P; Hosing C; Shpall EJ; Alousi A; Kebriaei P; Qazilbash M; Parmar S; Bashir Q; Shah N; Khouri I; Rondon G; Champlin R; Jones RB
Biol Blood Marrow Transplant; 2013 Mar; 19(3):410-7. PubMed ID: 23128322
[TBL] [Abstract][Full Text] [Related]
32. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
33. Endoplasmic reticulum stress could induce autophagy and apoptosis and enhance chemotherapy sensitivity in human esophageal cancer EC9706 cells by mediating PI3K/Akt/mTOR signaling pathway.
Zhou F; Li YH; Wang JJ; Pan J; Lu H
Tumour Biol; 2017 Jun; 39(6):1010428317705748. PubMed ID: 28631572
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
[TBL] [Abstract][Full Text] [Related]
35. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
36. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
37. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
38. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
40. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
